bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study

Service of Hematology, Valencia University General Hospital, Spain. BACKGROUND AND OBJECTIVE: bcl-2 oncoprotein plays a major physiological role in hemopoietic and non-hemopoietic cells by preventing apoptosis (programmed cell death). Disregulation of this process may be important in oncogenesis and...

Full description

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 83; no. 4; pp. 298 - 304
Main Authors Miguel-Garcia, A, Orero, T, Matutes, E, Carbonell, F, Miguel-Sosa, A, Linares, M, Tarin, F, Herrera, M, Garcia-Talavera, J, Carbonell-Ramon, F
Format Journal Article
LanguageEnglish
Published Italy 01.04.1998
Subjects
Adult
Aged
Aged, 80 and over
Female
Hematologic Neoplasms - metabolism
Hematologic Neoplasms - pathology
Humans
Lymphocytosis - metabolism
Male
Middle Aged
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Paraproteinemias - metabolism
Paraproteinemias - pathology
Plasma Cells - metabolism
Plasma Cells - pathology
Prognosis
Proto-Oncogene Proteins c-bcl-2 - biosynthesis
Survival Rate
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Service of Hematology, Valencia University General Hospital, Spain. BACKGROUND AND OBJECTIVE: bcl-2 oncoprotein plays a major physiological role in hemopoietic and non-hemopoietic cells by preventing apoptosis (programmed cell death). Disregulation of this process may be important in oncogenesis and the response to treatment of patients with different hematological malignancies. We have investigated the levels of bcl-2 expression in plasma cells from patients with reactive plasmacytosis (RP), monoclonal gammopathy of unknown significance (MGUS) and multiple myeloma (MM), correlating the bcl-2 expression and clinico-biological features in MM patients. DESIGN AND METHODS: The percentage of bcl-2 (+) plasma cells and levels of bcl-2 protein expression were investigated in 73 patients at diagnosis. Immunofluorescence and immunoenzymatic methods were applied using McAb against bcl-2 protein, and the intensity of protein expression was assessed by both the mean channel fluorescence intensity (MFI) and semiquantitative methods. To evaluate the intensity of bcl-2 expression in proliferating plasma cells, sequential double immunoenzymatic staining with McAb Ki-67 and bcl-2 was applied in 10 patients with MM. Correlations between bcl-2 expression and the clinico-biological features in MM patients were also studied. RESULTS: The proportion of bcl-2 (+) plasma cells was significantly higher in MGUS and MM than in RP (p
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0390-6078
1592-8721